WAYNE, PA — Teleflex Incorporated (NYSE: TFX) reported solid third-quarter 2025 financial results, highlighting continued growth across its global operations while announcing a new quarterly cash dividend.
The medical technology company posted third-quarter revenue of $913.0 million, up 19.4% year-over-year, with adjusted revenue of $892.9 million, a 16.8% increase. Adjusted diluted earnings per share from continuing operations rose to $3.67, compared to $3.49 in the prior-year period. However, GAAP results reflected a net loss, primarily driven by a $403.9 million non-cash goodwill impairment charge related to the company’s Interventional Urology business and a $100 million write-down of its Titan SGS asset group.
Chairman, President, and Chief Executive Officer Liam Kelly said the company delivered results in line with expectations despite softer-than-anticipated order rates in its intra-aortic balloon pump portfolio. He added that integration of the recently acquired Vascular Intervention business “remained on track,” and that the company continues to make progress toward separating into two entities—RemainCo and NewCo—as part of its long-term value creation strategy.
Revenue from the acquired Vascular Intervention business slightly exceeded guidance at $99 million for the quarter. Regionally, revenue growth was strongest in EMEA, up 55.9% year-over-year, followed by 25.0% growth in Asia and 7.8% in the Americas.
Teleflex ended the quarter with $381.3 million in total cash, cash equivalents, and restricted cash equivalents, up from $327.7 million at year-end 2024. The company maintained its full-year revenue growth outlook, narrowing its guidance to between 9.10% and 9.60%, with adjusted earnings per share projected in the range of $14.00 to $14.20.
In conjunction with its earnings release, Teleflex’s Board of Directors declared a quarterly cash dividend of $0.34 per share, payable December 15, 2025, to shareholders of record as of November 14, 2025.
Headquartered in Wayne, Pennsylvania, Teleflex develops medical technologies across anesthesia, emergency medicine, interventional cardiology, surgery, vascular access, and urology. Its portfolio includes trusted brands such as Arrow, Barrigel, LMA, QuikClot, Rüsch, UroLift, and Weck.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.